RT Journal Article
T1 First month prednisone dose predicts prednisone burden during the following 11 months: an observational study from the RELES cohort.
A1 Ruiz-Irastorza, G
A1 Garcia, M
A1 Espinosa, G
A1 Caminal, L
A1 Mitjavila, F
A1 González-León, R
A1 Sopeña, B
A1 Canora, J
A1 Villalba, M V
A1 Rodríguez-Carballeira, M
A1 López-Dupla, J M
A1 Callejas, J L
A1 Castro, A
A1 Tolosa, C
A1 Sánchez-García, M E
A1 Pérez-Conesa, M
A1 Navarrete-Navarrete, N
A1 Rodríguez, A P
A1 Herranz, M T
A1 Pallarés, L
K1 Corticosteroids
K1 Disease Activity
K1 Systemic Lupus Erythematosus
AB To study the influence of prednisone dose during the first month after systemic lupus erythematosus (SLE) diagnosis (prednisone-1) on glucocorticoid burden during the subsequent 11 months (prednisone-2-12). 223 patients from the Registro Español de Lupus Eritematoso Sistémico inception cohort were studied. The cumulative dose of prednisone-1 and prednisone-2-12 were calculated and recoded into a four-level categorical variable: no prednisone, low dose (up to 7.5 mg/day), medium dose (up to 30 mg/day) and high dose (over 30 mg/day). The association between the cumulative prednisone-1 and prednisone-2-12 doses was tested. We analysed whether the four-level prednisone-1 categorical variable was an independent predictor of an average dose >7.5 mg/day of prednisone-2-12. Adjusting variables included age, immunosuppressives, antimalarials, methyl-prednisolone pulses, lupus nephritis and baseline SLE Disease Activity Index (SLEDAI). Within the first month, 113 patients (51%) did not receive any prednisone, 24 patients (11%) received average low doses, 46 patients (21%) received medium doses and 40 patients (18%) received high doses. There was a strong association between prednisone-1 and prednisone-2-12 dose categories (p7.5 mg/day, while patients receiving low-dose prednisone-1 were not (adjusted OR 1.4, 95% CI 0. 0.38 to 5.2). If the analysis was restricted to the 158 patients with a baseline SLEDAI of ≥6, the model did not change. The dose of prednisone during the first month after the diagnosis of SLE is an independent predictor of prednisone burden during the following 11 months.
SN 2053-8790
YR 2016
FD 2016-08-02
LK https://hdl.handle.net/10668/27586
UL https://hdl.handle.net/10668/27586
LA en
DS RISalud
RD Apr 5, 2025